medigraphic.com

2009, Number 1

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2009; 47 (1)

Impaired Fasting Glucose Detection in Blood Donors Population

Munguía-Miranda C, Sánchez-Barrera RG, Tuz K, Alonso-García AL, Cruz M

Language: Spanish
References: 64
Page: 17-24
PDF size: 58.81 Kb.


ABSTRACT

Objective: to identify subjects with impaired fasting glucose (IFG), from a group of apparently healthy individuals.
Methods: a cross-sectional study was undertaken in 1188 blood donors, with no family history of diabetes (T2D). All these individuals were subjected to a questionnaire, and biochemical tests.
Results: the prevalence of IFG was 15.9 %, 17.1 % in men and 12.9 % in women. The average blood glucose levels in subjects with IFG were 107.2 ± 6.5 mg/dL in men and 106.0 ± 6.1 mg/dL in women. Sixty percent of individuals with IFG showed insulin resistance. The diagnosis of metabolic syndrome (MS) in IFG subjects was 20.2 %, according to the NCEP/ATP III criteria, 21.4 % according to the International Diabetes Federation criteria; and 29.3 % according to the American Heart Association and the National Heart, Lung and Blood Institute criteria. Seventy percent of the subjects with IFG showed hypertriglyceridemia, 51 % showed hypercholesterolemia and 85 % were over-weight or obese.
Conclusions: the prevalence of IFG was higher than expected, comparing with other populations reported in the literature. These apparently healthy subjects were not previously diagnosed and therefore have not received preventive actions to arrest the risk of T2D.


REFERENCES

  1. Burke JP, Williams K, Gaskill SP, Hazuda HP, Haffner SM, Stern MP. Rapid rise in the incidence of type 2 diabetes from 1987 to 1996: results from the San Antonio Heart Study. Arch Intern Med 1999;159(13):1450-1456.

  2. Stovring H, Andersen M, Beck-Nielsen H, Green A, Vach W. Rising prevalence of diabetes: evidence from a Danish pharmaco-epidemiological database. Lancet 2003;362(9383):537-538.

  3. Fox CS, Pencina MJ, Meigs JB, Vasan RS, Levitzky YS, Agostino RB. Trends in the incidence of type 2 diabetes mellitus from the 1970s to the 1990s. The Framingham Heart Study. Circulation 2006;113(25): 2914-2918.

  4. Mokdad AH, Ford ES, Bowman BA, Nelson DE, Engelgau MM, Vinicor F, Marks JS. Diabetes trends in the US: 1990-1998. Diabetes Care 2000;23(9): 1278-1283.

  5. Mokdad AH, Ford ES, Bowman BA, Nelson DE, Engelgau MM, Vinicor F, Marks JS. The continuing increase of diabetes in the US. [Letter.] Diabetes Care 2001;24(2):412.

  6. Mokdad AH, Bowman BA, Nelson DE, Engelgau MM, Vinicor F, Marks JS. The continuing epidemics of obesity and diabetes in the United States. JAMA 2001;286(10):1195-1200.

  7. Gerich JE. The genetic basis of type 2 diabetes mellitus: impaired insulin secretion versus impaired insulin sensitivity. Endocr Rev 1998;19(4): 491-503.

  8. Amos A, McCarty D, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabetes Med 1997; 14 Suppl 5:S1-S85.

  9. Centers for Disease Control and Prevention. Prevalence of diagnosed diabetes by age, United States, 1980-2000. Disponible en http://www.cdc.gov/diabetes/statistics/prev/national/fig2

  10. Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR, Wiedmeyer HM, Byrd-Holt DD. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults: the Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 1998:21(4):518-524.

  11. Mokdad AH, Ford ES, Bowman BA, Nelson DE, Engelgau MM, Vinicor F, Marks JS. Diabetes trends in the US: 1990-1998. Diabetes Care 2000;23(9): 1278-1283.

  12. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414(6865):782-787.

  13. World Health Organization. Report of a World Health Organization and International Diabetes Federation Meeting: screening for type 2 diabetes. Geneva: WHO; 2003.

  14. Centers for Disease Control and Prevention, National Diabetes Fact Sheet. General information and national estimates on diabetes in the United States, 2000. Atlanta, GA: Department of Health and Human Services, CDC; 2002.

  15. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998;21(9): 1414-1431.

  16. Geiss LS, Herman WH, Smith PJ. Mortality in non-insulin-dependent diabetes. En: Harris M, Cowie CC, Stern MP, et al. Diabetes in America. Second edition. Bethesda, MD, USA: National Institutes of Health; 1995. p. 233-255.

  17. Alberti KGMM. The costs of non-insulin-dependent diabetes mellitus. Diabet Med 1997;14(1):7-9.

  18. American Diabetes Association. Economic consequences of diabetes mellitus in the US in 1997. Diabetes Care 1998;21(2):296-309.

  19. Arredondo A, Zúñiga A. Economic consequences of epidemiological changes in diabetes in middleincome countries: the Mexican case. Diabetes Care 2004;27(1):104-109.

  20. Genuth S, Alberti KG, Bennett P, Buse J, DeFronzo R, Kahn R, et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003;26(11): 3160-3167.

  21. Vendrame F, Gottlieb PA. Prediabetes: prediction and prevention trials. Endocrinol Metab Clin North Am 2004;33(1):75-92.

  22. Davidson MB, Landsman PB, Alexander CM. Lowering the criterion for impaired fasting glucose will not provide clinical benefit. Diabetes Care 2003;26(12):3329-3330.

  23. Schringer DL, Lorber B. Lowering the cut point for impaired fasting glucose: where is the evidence? Where is the logic? Diabetes Care 2004; 27(2):592-601.

  24. Abdul-Ghani MA, Tripathy D, DeFronzo RA. Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care 2006;29(5):1130-1139.

  25. Unwin N, Shaw J, Zimmet P, Alberti KG. Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med 2002;19(9):708-723.

  26. Sánchez-Castillo CP, Velázquez-Monroy O, Berber A, Lara-Esqueda A, Tapia-Conyer R, James WP. Encuesta Nacional de Salud (ENSA) 2000 Working Group. Anthropometric cutoff points for predicting chronic diseases in the Mexican National Health Survey 2000. Obes Res 2003; 11(3):442-451.

  27. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288(21):2709-2716.

  28. Malik S, Wong ND, Franklin SS, Kamath TV, L'Italien GJ, Pio JR, Williams GR. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004; 110(10):1245-1250.

  29. Hunt KJ, Reséndez RG, Williams K, Haffner SM, Stern MP. San Antonio Heart Study. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to allcause and cardiovascular mortality in the San Antonio Heart Study. Circulation 2004;110(10):1251-1257.

  30. Reaven G. The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. Endocrinol Metab Clin North Am 2004;33(2):283-303.

  31. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365(9468):1415-1428.

  32. Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR, Wiedmeyer HM, Byrd- Holt DD. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey 1988-1994. Diabetes Care 1998;21(4):518-524.

  33. Franse LV, Di Bari M, Shorr RI, Resnick HE, van Eijk JT, Bauer DC, Newman AB, Pahor M. Type 2 diabetes in older well-functioning people: who is undiagnosed? Data from the health, aging, and body composition study. Diabetes Care 2001; 24(12)2065-2070.

  34. Franse LV, Bari MD, Shorr RI, Resnick HE, van Eijk JT, Bauer DC, Newman AB, Pahor M. Type 2 diabetes in older well-functioning people: who is undiagnosed? Data from the health, aging, and body composition study. Diabetes Care 2001;24: 2065-2070.

  35. Aguilar-Salinas CA, Gómez-Pérez FJ. Declaración de Acapulco: propuesta para la reducción de la incidencia de la diabetes en México. Rev Invest Clin 2006;58(1):71-77.

  36. Aguilar-Salinas CA, Velázquez-Monroy O, Gómez- Pérez FJ, González-Chávez A, Esqueda AL, Molina- Cuevas V, Rull-Rodrigo JA, Tapia-Conyer R. Encuesta Nacional de Salud 2000 Group. Characteristics of patients with type 2 diabetes in México: results from a large population-based nationwide survey. Diabetes Care 2003;26(7): 2021-2026.

  37. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003;26(11): 3160-3167.

  38. Guerrero-Romero F, Rodríguez-Morán M. Lowered criterion for normal fasting plasma glucose: impact on the detection of impaired glucose tolerance and metabolic syndrome. Arch Med Res 2006:37(1);140-144.

  39. Olaiz-Fernández G, Rivera-Dommarco J, Shamab- Levy T, et al. Encuesta Nacional de Salud y Nutrición 2006 (ENSANUT 2006). Cuernavaca, Morelos, México: Instituto Nacional de Salud Pública; 2006. p. 131.

  40. Lillioja S, Mott DM, Spraul M, Ferrano R, Foley JE, Ravussin E, et al. Insulin resistance and insulin secretory dysfunction as precursors of noninsulin- dependent diabetes mellitus. Prospective Studies of Pima Indians. N Engl J Med 1993; 329(27):1988-1992.

  41. Chiasson JL, Rabasa-Lhoret R. Prevention of type 2 diabetes. Diabetes 2004;53 Suppl 3:S34-S38.

  42. Cline GW, Petersen KF, Krssak M, Shen J, Hundal RS, Trajanoski Z, et al. Impaired glucose transport as a cause of decreased insulinstimulated muscle glycogen synthesis in type 2 diabetes. N Engl J Med 1999;341(4):240-246.

  43. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adults Treatment Panel III). Executive summary of the third report of the National Cholesterol Education Program (NCEP). JAMA 2001;285(5): 2486-2497.

  44. Hillier TA, Fagot-Campagna A, Eschwege E, Vol S, Cailleau M, Balkau B; the DESIR Study group. Weight change and changes in the metabolic syndrome as the French population moves towards overweight: the DESIR cohort. Int J Epidemiol 2006;35(1): 190-196.

  45. He Y, Jiang B, Wang J, Feng K, Chang Q, Fan L, et al. Prevalence of the metabolic syndrome and its relation to cardiovascular disease in an elderly Chinese population. JACC 2006;47(8):1588-1594.

  46. Tan CE, Ma S, Wai D. Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians? Diabetes Care 2004;27(5):1182-1186.

  47. Deepa M, Farooq S, Datta M, Deepa R, Mohan V. Prevalence of metabolic syndrome using WHO, ATPIII and IDF definitions in Asian Indians: The Chennai Urban Rural Epidemiology Study (CURES-34). Diabetes Metab Res Rev 2007; 23(2):127-134.

  48. Lorenzo C, Williams K, González-Villalpando C, Haffner SM. The prevalence of the metabolic syndrome did not increase in Mexico City between 1990-1992 and 1997-1999 despite more central obesity. Diabetes Care 2005;28(10):2480-2485.

  49. Sowers JR. Obesity a cardiovascular risk factor. Am J Med 2003;115 Suppl 8A:37S-41S.

  50. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24(4): 683-689.

  51. Midthjell K, Krüger O, Holmen J, Tverdal A, Claudi T, Bjorndal, A, Magnus P. Rapid changes in the prevalence of obesity known diabetes in an adult Norwegian population. The Nord-Trondelag Health Surveys: 1984-1986 and 1995-1997. Diabetes Care 1999;22(11):1813-1820.

  52. Mokdad AH, Bowman BA, Ford ES Vinicor F, Marks JS, Kaplan JP. The continuing epidemics of obesity and diabetes in the United States. JAMA 2000;286(10):195-2000.

  53. Bjorntorp P. Obesity. Lancet 1997;350(9075):423-426.

  54. Hensrud DD. Dietary treatment and long term weight loss and maintenance in type 2 diabetes. Obes Res 2001;9(Suppl 4):348S-353S.

  55. Benjamin SM, Valdez R, Geiss LS, Rolka DB, Narayan KM. Estimated number of adults with prediabetes in US in 2000. Diabetes Care 2003; 26(3):645-649.

  56. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, Marks JS. Prevalence of obesity, diabetes and obesity-related health risk factors. JAMA 2003;289(1):76-79.

  57. Tziakas DN, Chalikias GK, Kaski JC. Epidemiology of the diabetic heart. Coronary Artery Disease 2005;16(Suppl 1):S3-S10.

  58. Fruchart JC, Nierman MC, Stroes ES, Kastelein JJ, Duriez P. New risk factors for atherosclerosis and patient risk assessment. Circulation 2004; 109 (23 Suppl III):III-15–III-19.

  59. Zhang P, Engelgau MM, Valdez R, Benjamin SM, Cadwell B, Narayan KM. Costs of screening for pre-diabetes among US adults: a comparison of different screening strategies. Diabetes Care 2003; 26(9):2536-2542.

  60. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346(6):393-403.

  61. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, et al; Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344(18):1343-1350.

  62. World Health Organization. What resources are handed? En: World Health Report 2000, Health Systems: improving performance. Geneva: WHO; 2000. p. 73-77.

  63. Sassi F, Archard L, Le Grand J. Economic evaluation of health care: Research questions. Department of Social Policy and Social Care. London UK: The London School of Economics and Political Science; 2001. p. 35-46.

  64. Harris MI, Eastman RC. Early detection of undiagnosed non-insulin-dependent diabetes mellitus. JAMA 1996;276(15):1261-1262.




2020     |     www.medigraphic.com